We also show that tranilast is effective at inhibiting CSCs of triple-negative (ER−/PR−/HER-2−) breast cancer cell lines (MDA-MB-231, SUM149 and SUM159) or a triple-positive cell line (ER+/PR+/HER-2+) (BT474). Here, ERBB2 is linked to breast cancer.